Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 2 study of MultiStem cell therapy for early treatment and prevention of complications after severe traumatic injury

Trial Profile

A phase 2 study of MultiStem cell therapy for early treatment and prevention of complications after severe traumatic injury

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 27 Apr 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Allogeneic stem cell therapy Athersys (Primary)
  • Indications Traumatic brain injuries
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Most Recent Events

    • 27 Apr 2018 New trial record
    • 23 Apr 2018 According to a University of Texas Health Science Center media release, this proposed Phase 2 clinical trial must still go through review and approval by the U.S. Food and Drug Administration (FDA) and other relevant regulators.
    • 23 Apr 2018 According to a University of Texas Health Science Center media release, Medical Technology Enterprise Consortium (MTEC) and Memorial Hermann Foundation has provided the fund to the University of Texas Health Science Center to conduct this study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top